One of the challenges in treating melanoma patients with mitogen-activated protein kinase inhibitors (MAPKis), which target MAPK signaling pathways, is the development of drug resistance due to the activation of the signal transducer and activator of the transcription 3 (STAT3) signaling pathway. Here, STAT3 is linked to melanoma.